Magdalena Staniszewska

Prof. Magdalena Staniszewska

Institute of Health Sciences Faculty of Medicine, The John Paul II Catholic University of Lublin, Lublin, Lubelskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
MFMarni J. Falk
Marni J. Falk
QZQi Zhang
Qi Zhang
ENEiko Nakamaru-Ogiso
Eiko Nakamaru-Ogiso
CKChitra Kannabiran
Chitra Kannabiran
ZFZoe Fonseca-Kelly
Zoe Fonseca-Kelly
EPEric A Pierce
Eric A Pierce
Eric Pierce, Xiaowu Gai and colleagues identify mutations in NMNAT1 as a new cause of Leber congenital amaurosis, an early-onset form of retinal degeneration. NMNAT1 encodes an isoform of nicotinamide mononucleotide adenylyltransferase, which is required for nicotinamide adenine dinucleotide (NAD+) biosynthesis. Leber congenital amaurosis (LCA) is an infantile-onset form of inherited retinal degeneration characterized by severe vision loss1,2. Two-thirds of LCA cases are caused by mutations in 17 known disease-associated genes3 (Retinal Information Network (RetNet)). Using exome sequencing we identified a homozygous missense mutation (c.25G>A, p.Val9Met) in NMNAT1 that is likely to be disease causing in two siblings of a consanguineous Pakistani kindred affected by LCA. This mutation segregated with disease in the kindred, including in three other children with LCA. NMNAT1 resides in the previously identified LCA9 locus and encodes the nuclear isoform of nicotinamide mononucleotide adenylyltransferase, a rate-limiting enzyme in nicotinamide adenine dinucleotide (NAD+) biosynthesis4,5. Functional studies showed that the p.Val9Met alteration decreased NMNAT1 enzyme activity. Sequencing NMNAT1 in 284 unrelated families with LCA identified 14 rare mutations in 13 additional affected individuals. These results are the first to link an NMNAT isoform to disease in humans and indicate that NMNAT1 mutations cause LCA.

1 August 2010 in Redox Report
Verified
Journal Article
Closed access
DBDavid J. Bonda
David J. Bonda
MMManeesh Mailankot
Maneesh Mailankot
JSJeremy G. Stone
Jeremy G. Stone
MGMatthew R. Garrett
Matthew R. Garrett
Magdalena StaniszewskaMagdalena Staniszewska
Magdalena Staniszewska
MSMark A. Smith
Mark A. Smith
Tryptophan metabolism, through the kynurenine pathway, produces neurotoxic intermediates that are implicated in the pathogenesis of Alzheimer's disease. In particular, oxidative stress via 3-hydroxykynurenine (3-HK) and its cleaved product 3-hydroxyanthranilic acid (3-HAA) significantly damages neuronal tissue and may potentially contribute to a cycle of neurodegeneration through consequent amyloid-β accumulation, glial activation, and up-regulation of the kynurenine pathway. To determine the role of the kynurenine pathway in eliciting and continuing oxidative stress within Alzheimer's diseased brains, we used immunocytochemical methods to show elevated levels of 3-HK modifications and the upstream, rate-limiting enzyme indoleamine 2,3-dioxygenase (IDO-1) in Alzheimer's diseased brains when compared to controls. Importantly, the association of IDO-1 with senile plaques was confirmed and, for the first time, IDO-1 was shown to be specifically localized in conjunction with neurofibrillary tangles. As senile plaques and neurofibrillary tangles are the pathological hallmarks of Alzheimer's disease, our study provides further evidence that the kynurenine pathway is involved with the destructive neurodegenerative pathway of Alzheimer's disease.

26 June 2017 in Journal of Separation Science
Verified
Journal Article
Open access
PDF file
Ilona SadokIlona Sadok
Ilona Sadok
AGAndrzej Gamian
Andrzej Gamian
Magdalena StaniszewskaMagdalena Staniszewska
Magdalena Staniszewska
The kynurenine pathway generates multiple tryptophan metabolites called collectively kynurenines and leads to formation of the enzyme cofactor nicotinamide adenine dinucleotide. The first step in this pathway is tryptophan degradation, initiated by the rate‐limiting enzymes indoleamine 2,3‐dioxygenase, or tryptophan 2,3‐dioxygenase, depending on the tissue. The balanced kynurenine metabolism, which has been a subject of multiple studies in last decades, plays an important role in several physiological and pathological conditions such as infections, autoimmunity, neurological disorders, cancer, cataracts, as well as pregnancy. Understanding the regulation of tryptophan depletion provide novel diagnostic and treatment opportunities, however it requires reliable methods for quantification of kynurenines in biological samples with complex composition (body fluids, tissues, or cells). Trace concentrations, interference of sample components, and instability of some tryptophan metabolites need to be addressed using analytical methods. The novel separation approaches and optimized extraction protocols help to overcome difficulties in analyzing kynurenines within the complex tissue material. Recent developments in chromatography coupled with mass spectrometry provide new opportunity for quantification of tryptophan and its degradation products in various biological samples. In this review, we present current accomplishments in the chromatographic methodologies proposed for detection of tryptophan metabolites and provide a guide for choosing the optimal approach.

1 July 2016 in The American Journal of Pathology
Verified
Journal Article
Closed access
SGScott H. Greenwald
Scott H. Greenwald
JCJeremy R. Charette
Jeremy R. Charette
Magdalena StaniszewskaMagdalena Staniszewska
Magdalena Staniszewska
LSLan Ying Shi
Lan Ying Shi
SBSteve D.M. Brown
Steve D.M. Brown
EPEric A. Pierce
Eric A. Pierce

1 April 2018 in Food Chemistry
Verified
Journal Article
Closed access
Ilona SadokIlona Sadok
Ilona Sadok
ASAgnieszka Szmagara
Agnieszka Szmagara
Magdalena StaniszewskaMagdalena Staniszewska
Magdalena Staniszewska

5 January 2024 in Materials
Verified
Journal Article
Open access
PDF file
AMAnna Michalicha
Anna Michalicha
ABAnna Belcarz
Anna Belcarz
Dimitrios A. GiannakoudakisDimitrios A. Giannakoudakis
Dimitrios A. Giannakoudakis
Magdalena StaniszewskaMagdalena Staniszewska
Magdalena Staniszewska
Mariusz BarczakMariusz Barczak
Mariusz Barczak
Effective wound treatment has become one of the most important challenges for healthcare as it continues to be one of the leading causes of death worldwide. Therefore, wound care technologies significantly evolved in order to provide a holistic approach based on various designs of functional wound dressings. Among them, hydrogels have been widely used for wound treatment due to their biocompatibility and similarity to the extracellular matrix. The hydrogel formula offers the control of an optimal wound moisture level due to its ability to absorb excess fluid from the wound or release moisture as needed. Additionally, hydrogels can be successfully integrated with a plethora of biologically active components (e.g., nanoparticles, pharmaceuticals, natural extracts, peptides), thus enhancing the performance of resulting composite hydrogels in wound healing applications. In this review, the-state-of-the-art discoveries related to stimuli-responsive hydrogel-based dressings have been summarized, taking into account their antimicrobial, anti-inflammatory, antioxidant, and hemostatic properties, as well as other effects (e.g., re-epithelialization, vascularization, and restoration of the tissue) resulting from their use.